Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15830MR)

This product GTTS-WQ15830MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15830MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6259MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ13849MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ7428MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ916MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ2023MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ5003MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ6518MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ4266MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW